Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myelodysplastic-Myeloproliferative Diseases
Description
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS. MeSH
Hierarchy View
Subtype Terms (3)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
129 drugs (101 approved, 28 experimental)
Leukemia, Myelomonocytic, Chronic
216 drugs (116 approved, 100 experimental)
Leukemia, Myelomonocytic, Juvenile
56 drugs (40 approved, 16 experimental)
Approved Indicated Drugs (1)
Phase 2 Indicated Drugs (32)
Organization Involved with Phase 3 Indications (22)
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
European Organisation for Research and Treatment of Cancer
Organization Involved with Phase 2 Indications (39)
Korea Research Institute of Bioscience & Biotechnology
Memorial Sloan-Kettering Cancer Center
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
